Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response

June 3, 2024

https://www.prnewswire.com/news-releases/precigen-announces-groundbreaking-pivotal-study-data-for-prgn-2012-in-patients-with-recurrent-respiratory-papillomatosis-in-which-more-than-half-of-patients-achieved-complete-response-302161493.html

–   Phase 1/2 pivotal study met the primary safety and efficacy endpoints –

–   51% (18 out of 35) of patients achieved Complete Response, requiring no surgeries after treatment with PRGN-2012; complete responses have been durable beyond 12 months with median duration of follow up of 20 months as of data cutoff –

Read more at prnewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.